Oncology firm Delcath Systems' Q3 revenue beats on Hepzato growth
DCTH•DCTH•DCTH•DCTH•Delcath Systems reported Q3 revenue of $35.1 million, beating the $26.03 million analyst estimate, as HEPZATO KIT volume rose 72% year over year. The company raised its 2026 revenue guidance to $115 million-$117 million and expects full-year adjusted EBITDA to be positive.
Delcath Systems' Q3 revenue was $35.1 million, above the $26.03 million consensus estimate. Net income was $6.95 million, operating income was $7.12 million, and adjusted EBITDA more than doubled from a year earlier.
The company said revenue growth was driven by a 72% year-over-year increase in HEPZATO KIT volume, along with more active treatment centers and greater engagement. Gross margin rose to 89% from 87% a year earlier. Delcath raised its 2026 revenue guidance to $115 million-$117 million and expects gross margin of 87%-89% and positive adjusted EBITDA for the full year.
